KR20090086060A - 단백질의 경구 또는 직장 투여를 위한 약학적 조성물 - Google Patents

단백질의 경구 또는 직장 투여를 위한 약학적 조성물 Download PDF

Info

Publication number
KR20090086060A
KR20090086060A KR1020097007396A KR20097007396A KR20090086060A KR 20090086060 A KR20090086060 A KR 20090086060A KR 1020097007396 A KR1020097007396 A KR 1020097007396A KR 20097007396 A KR20097007396 A KR 20097007396A KR 20090086060 A KR20090086060 A KR 20090086060A
Authority
KR
South Korea
Prior art keywords
tnfα
active ingredient
intestinal
protein
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097007396A
Other languages
English (en)
Korean (ko)
Inventor
마우로 아자니
루이기 모로
로베르또 빌라
Original Assignee
코스모 테크놀러지스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI20061741 external-priority patent/ITMI20061741A1/it
Priority claimed from ITMI20071205 external-priority patent/ITMI20071205A1/it
Application filed by 코스모 테크놀러지스 리미티드 filed Critical 코스모 테크놀러지스 리미티드
Publication of KR20090086060A publication Critical patent/KR20090086060A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020097007396A 2006-09-12 2007-09-07 단백질의 경구 또는 직장 투여를 위한 약학적 조성물 Withdrawn KR20090086060A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITMI2006A001741 2006-09-12
ITMI20061741 ITMI20061741A1 (it) 2006-09-12 2006-09-12 Composizioni farmaceutiche per la somministrazione orale di sostanze proteiche
ITMI2007A001205 2007-06-15
ITMI20071205 ITMI20071205A1 (it) 2007-06-15 2007-06-15 Composizioni farmaceutiche per la somministrazione orale o rettale di sostanze proteiche

Publications (1)

Publication Number Publication Date
KR20090086060A true KR20090086060A (ko) 2009-08-10

Family

ID=39107203

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097007396A Withdrawn KR20090086060A (ko) 2006-09-12 2007-09-07 단백질의 경구 또는 직장 투여를 위한 약학적 조성물

Country Status (8)

Country Link
US (1) US20100004157A1 (https=)
EP (1) EP2081555A2 (https=)
JP (1) JP2010502759A (https=)
KR (1) KR20090086060A (https=)
CA (1) CA2663548A1 (https=)
MX (1) MX2009002756A (https=)
RU (1) RU2009113557A (https=)
WO (1) WO2008031770A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12203056B2 (en) 2008-03-28 2025-01-21 Ecolab Usa Inc. Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents
US8809392B2 (en) 2008-03-28 2014-08-19 Ecolab Usa Inc. Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents
GB201017048D0 (en) * 2010-10-08 2010-11-24 Ucl Business Plc Composition
US10946091B2 (en) * 2012-06-04 2021-03-16 Gaurav Agrawal Compositions and methods for treating Crohn's disease and related conditions and infections
EP3142645A4 (en) * 2014-05-15 2017-12-27 Rani Therapeutics, LLC Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10689460B2 (en) 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
HK1250011A1 (zh) 2015-03-31 2018-11-23 Sorriso Pharmaceuticals, Inc. 具有蛋白酶可切割接头的肽构建体
AU2016257813B2 (en) * 2015-05-01 2021-05-13 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
AU2016261599B2 (en) * 2015-05-08 2021-08-26 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
JP7224917B2 (ja) * 2016-03-31 2023-02-20 ソリッソ ファーマシューティカルズ，インク． 組成物
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
CA3045310A1 (en) * 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
EP3501503A1 (en) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Solid delivery composition
WO2020254827A1 (en) 2019-06-21 2020-12-24 Vhsquared Limited Polypeptides
JP7680377B2 (ja) 2019-06-21 2025-05-20 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
KR20220063148A (ko) 2019-06-21 2022-05-17 소리소 파마슈티컬스 인크. 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
AU698393B2 (en) * 1994-06-24 1998-10-29 Immunex Corporation Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
EP1183014B1 (en) * 1999-06-14 2003-10-08 Cosmo S.p.A. Controlled release and taste masking oral pharmaceutical compositions
JP2005510542A (ja) * 2001-11-30 2005-04-21 ファイザー・プロダクツ・インク 炎症の治療のための、ｉｌ−１／１８阻害剤及びｔｎｆ阻害剤の組み合わせ。
ITMI20012599A1 (it) * 2001-12-11 2003-06-11 Cosmo Spa Composizioni farmaceutiche per la somministrazione orale di eparina osuoi derivati, utili per la terapia di malattie infiammatorie dell'int
EA200600598A1 (ru) * 2003-09-19 2006-08-25 Пенвест Фармасьютикалз Ко. Лекарственные формы замедленного высвобождения
WO2006009764A1 (en) * 2004-06-17 2006-01-26 Amano Enzyme Usa., Ltd. Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers
US7879361B2 (en) * 2005-01-04 2011-02-01 Gp Medical, Inc. Nanoparticles for drug delivery
DE602006020123D1 (de) * 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga

Also Published As

Publication number Publication date
CA2663548A1 (en) 2008-03-20
EP2081555A2 (en) 2009-07-29
WO2008031770A3 (en) 2008-09-12
WO2008031770A2 (en) 2008-03-20
US20100004157A1 (en) 2010-01-07
MX2009002756A (es) 2009-05-25
JP2010502759A (ja) 2010-01-28
RU2009113557A (ru) 2010-10-20

Similar Documents

Publication Publication Date Title
KR20090086060A (ko) 단백질의 경구 또는 직장 투여를 위한 약학적 조성물
JP7377624B2 (ja) アンチセンス組成物およびその作製および使用
US20040018190A1 (en) Drugs and foods improving the quality of life and process for producing the same
JPH11510506A (ja) 結腸からの極性薬剤の摂取を増強するための組成物
CN101360495B (zh) 对癌症病人给药mTOR抑制剂
EP2642978A2 (en) Immunomodulatory compositions comprising hydralazine for the treatment of gastrointestinal disorders
JP2020500870A (ja) 乳酸カルシウム組成物および使用法
JP2024016193A (ja) 活性剤の送達のための乾燥剤を含む経口製剤
CN114668839A (zh) 包含phy906提取物、黄芩提取物或来自这些提取物的化合物的联合疗法
Xiong et al. Fibrosis in fat: from other diseases to Crohn’s disease
EP2651414A1 (en) Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer
JP7419333B2 (ja) メタ亜ヒ酸塩を含む医薬組成物および製造方法
JP2024050581A (ja) 腫瘍の増殖及び転移を阻害するためのコルヒチンの使用
CN120112280A (zh) 用于口服递送的组合物
CN101534800A (zh) 用于口服或直肠施用蛋白质物质的药物组合物
KR20120098906A (ko) 서방성 제제
KR102485766B1 (ko) 생체이용률이 향상된 피오글리타존 함유 약학조성물
CN106310287A (zh) 新利司他药用组合物及其制备方法
WO2016095592A1 (zh) 一种治疗实体肿瘤的卡莫司汀缓释植入剂及其制备方法
CN113440614A (zh) 一种用于治疗类风湿性关节炎的组合物及其应用
CN116602978B (zh) 一种治疗胰腺炎的药物及其制备方法
HK40103513A (zh) 包含乳酸钙的药物组合物及其用途
Abutbul et al. Colon-Targeted Delivery Systems
ITMI20071205A1 (it) Composizioni farmaceutiche per la somministrazione orale o rettale di sostanze proteiche
CN106692160A (zh) 肝再生的治疗剂

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090410

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid